Serum PARC/CCL-18 Concentrations and Health Outcomes in Chronic Obstructive Pulmonary Disease

Sin, Don D.; Miller, Bruce E.; Duvoix, Annelyse; Man, S. F. Paul; Zhang, Xuekui; Silverman, Edwin K.; Connett, John E.; Anthonisen, Nicholas A.; Wise, Robert A.; Tashkin, Donald P.; Celli, Bartolomé R.; Edwards, Lisa; Locantore, Nicholas; MacNee, William; Tal‐Singer, Ruth; Lomas, David A.

doi:10.1164/rccm.201008-1220oc

Cited by 102 publications

(97 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 13 metabolic analytes combined with five MetSyn clinical parameters had a sensitivity of 41%, suggesting that other pathways to lung disease remain unidentified in this analysis. Serum inflammatory biomarkers are also elevated in COPD exacerbations (49)(50)(51). We have recently reported that low a 1 -antitrypsin, elevated granulocyte-macrophage colonystimulating factor, and macrophage-derived chemokine are additional risk factors for the development of WTC-related lung injury (52)(53)(54).…”

Section: Discussionmentioning

confidence: 99%

Metabolic Syndrome Biomarkers Predict Lung Function Impairment

Naveed

Weiden

Kwon

et al. 2012

Am J Respir Crit Care Med

113

View full text Add to dashboard Cite

Rationale:Cross-sectional studies demonstrate an association between metabolic syndrome and impaired lung function. Objectives: To define if metabolic syndrome biomarkers are risk factors for loss of lung function after irritant exposure. Methods: A nested case-control study of Fire Department of New York personnel with normal pre-September 11th FEV 1 and who presented for subspecialty pulmonary evaluation before March 10, 2008. We correlated metabolic syndrome biomarkers obtained within 6 months of World Trade Center dust exposure with subsequent FEV 1 . FEV 1 at subspecialty pulmonary evaluation within 6.5 years defined disease status; cases had FEV 1 less than lower limit of normal, whereas control subjects had FEV 1 greater than or equal to lower limit of normal. Measurements and Main Results: Clinical data and serum sampled at the first monitoring examination within 6 months of September 11, 2001, assessed body mass index, heart rate, serum glucose, triglycerides and high-density lipoprotein (HDL), leptin, pancreatic polypeptide, and amylin. Cases and control subjects had significant differences in HDL less than 40 mg/dl with triglycerides greater than or equal to 150 mg/dl, heart rate greater than or equal to 66 bpm, and leptin greater than or equal to 10,300 pg/ml. Each increased the odds of abnormal FEV 1 at pulmonary evaluation by more than twofold, whereas amylin greater than or equal to 116 pg/ml decreased the odds by 84%, in a multibiomarker model adjusting for age, race, body mass index, and World Trade Center arrival time. This model had a sensitivity of 41%, a specificity of 86%, and a receiver operating characteristic area under the curve of 0.77. Conclusions: Abnormal triglycerides and HDL and elevated heart rate and leptin are independent risk factors of greater susceptibility to lung function impairment after September 11, 2001, whereas elevated amylin is protective. Metabolic biomarkers are predictors of lung disease, and may be useful for assessing risk of impaired lung function in response to particulate inhalation.

show abstract

Section: Discussionmentioning

confidence: 99%

Metabolic Syndrome Biomarkers Predict Lung Function Impairment

Naveed

Weiden

Kwon

et al. 2012

Am J Respir Crit Care Med

113

View full text Add to dashboard Cite

show abstract

“…In a small study of patients with mild to moderate COPD, serum pulmonary and activation-regulated chemokine/CC-chemokine ligand-18 (PARC/CCL-18) was significantly associated with reduced FEV1, increased risk of exacerbations, and an increased BODE index (Pinto-Plata et al 2007). There is also recent evidence that elevated levels of PARC/CCL-18 are associated with increased risk of cardiovascular hospitalizations or mortality in the lung health study (LHS) cohort and with total mortality in the ECLIPSE cohort (Sin et al 2011). Circulating levels of PARC/CCL-18 have been found to be associated with acute exacerbations (Hurst et al 2006).…”

Section: C-reactive Proteinmentioning

confidence: 99%

Blood Specimen Biomarkers of Inflammation, Matrix Degradation, Angiogenesis, and Cardiac Involvement: a Future Useful Tool in Assessing Clinical Outcomes of COPD Patients in Clinical Practice?

Kristan

2013

Arch. Immunol. Ther. Exp.

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is not fully reversible; this airflow limitation is both progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gasses. COPD is undoubtedly an umbrella term, and it seems unlikely that all patients with COPD have the same underlying disease processes; thus, there is a need for differential treatment of different subgroups. A potential solution is to find modifiable biomarkers that can assist in drug development and distinguish subgroups of COPD. With the exception of lung function tests, there are currently no well-validated biomarkers or surrogate endpoints that can be used to establish the efficacy of a drug for COPD. This article discusses biomarkers of inflammation (fibrinogen, C-reactive protein, pulmonary and activation-regulated chemokine/CC-chemokine ligand-18, serum surfactant protein D, interleukin (IL)-6, IL-8 and tumor necrosis factor a, complement factor C5a), angiogenesis factors as a part of the pathogenetic aspect in this disease (vascular endothelial growth factor, angiogenin, and IL-8), and matrix degradation biomarkers. Troponin and natriuretic peptides are presented as biomarkers of cardiac involvement in the light of COPD comorbidities. Trials based on research on known clinical variables such as FEV1, BODE, and 6MWT in combination with biomarkers from lung and blood specimens will probably clarify part of the prognosis and natural history of the disease. This will also represent an additional step in COPD phenotyping and new treatment possibilities.

show abstract

Section: Cc-chemokine Ligand-18 (Or Pulmonary and Activation-regulatementioning

confidence: 99%

“…10,11,38 CCL-18 is also associated with clinical outcomes, including cardiovascular morbidity, overall mortality and response to treatment. 38,39 However, it is unclear what role this chemokine may play in disease pathogenesis. 38 Biomarker Panels: In addition to the hypothesisdriven research detailed in the previous section s, the use of newer high-throughput techniques has led to the discovery of a number of candidate biomarkers that are under investigation.…”

Section: Cc-chemokine Ligand-18 (Or Pulmonary and Activation-regulatementioning

confidence: 99%

“…38,39 However, it is unclear what role this chemokine may play in disease pathogenesis. 38 Biomarker Panels: In addition to the hypothesisdriven research detailed in the previous section s, the use of newer high-throughput techniques has led to the discovery of a number of candidate biomarkers that are under investigation. Bon and colleagues 40 used a multiplex protein array to identify signifi cant associations between several serum infl ammatory proteins and quantitative radiographic measurements of FEV 1 % (including matrix metalloproteinase [MMP]-1 and MMP-7), airway thickening (including IL-6 and CRP), and parenchymal emphysema (IL-6, TNF-a , and MMP-7).…”

Section: Cc-chemokine Ligand-18 (Or Pulmonary and Activation-regulatementioning

confidence: 99%

See 1 more Smart Citation

The Expanding Role of Biomarkers in the Assessment of Smoking-Related Parenchymal Lung Diseases

Doyle

Pinto-Plata

Morse

et al. 2012

Chest

Self Cite

View full text Add to dashboard Cite

Recent advances in the fi eld of clinical biomarkers suggest that quantifi cation of serum proteins could play an important role in the diagnosis, classifi cation, prognosis, and treatment response of smoking-related parenchymal lung diseases. COPD and idiopathic pulmonary fi brosis (IPF), two common chronic progressive parenchymal lung diseases, share cigarette smoke exposure as a common dominant risk factor for their development. We have recently shown that COPD and interstitial lung disease may represent distinct outcomes of chronic tobacco use, whereas others have demonstrated that both diseases coexist in some individuals . In this perspective, we examine the potential role of peripheral blood biomarkers in predicting which individuals will develop COPD or IPF, as well as their usefulness in tracking disease progression and exacerbations. Additionally, given the current lack of sensitive and effective metrics to determine an individual's response to treatment, we evaluate the potential role of biomarkers as surrogate markers of clinical outcomes. Finally, we examine the possibility that changes in levels of select protein biomarkers can provide mechanistic insight into the common origins and unique individual susceptibilities that lead to the development of smoking-related parenchymal lung diseases. This discussion is framed by a consideration of the properties of ideal biomarkers for different clinical and research purposes and the best uses for those biomarkers that have already been proposed and investigated.CHEST 2012; 142(4):1027-1034Abbreviations: BODE 5 BMI, airfl ow obstruction, dyspnea, and exercise capacity; CCL-18 5 CC-chemokine ligand-18; CRP 5 C-reactive protein; IPF 5 idiopathic pulmonary fi brosis; KL-6 5 Krebs von den Lungen-6; MMP 5 matrix metalloproteinase; SP 5 surfactant protein; TNF-a 5 tumor necrosis factor-a

show abstract

Serum PARC/CCL-18 Concentrations and Health Outcomes in Chronic Obstructive Pulmonary Disease

Cited by 102 publications

References 27 publications

Metabolic Syndrome Biomarkers Predict Lung Function Impairment

Metabolic Syndrome Biomarkers Predict Lung Function Impairment

Blood Specimen Biomarkers of Inflammation, Matrix Degradation, Angiogenesis, and Cardiac Involvement: a Future Useful Tool in Assessing Clinical Outcomes of COPD Patients in Clinical Practice?

The Expanding Role of Biomarkers in the Assessment of Smoking-Related Parenchymal Lung Diseases

Contact Info

Product

Resources

About